Avalo Therapeutics Inc. Insider Trading

AVTX

Last 12 months

Insiders sold $8.5M and bought nothing on the open market.

97% of the selling was scheduled in advance under 10b5-1 plans. Director Jonathan Goldman sold 163K on Nov 14, 2025, 100% of their stake, outside a plan. The last open-market buy by an executive or director was in Nov 2024.

Net open-market

−$8.5M

0 buys · 23 sales

Under a 10b5-1 plan

97%

of the value sold

Insiders who bought / sold

0 / 6

executives and directors

Last open-market buy

Nov 2024

Nov 13, 2024

Get an email when AVTX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 16	Christopher Ryan Sullivan Chief Financial Officer	Sold10b5-1 plan	12,394	$16.33	202K	24%	Form 4
Sep 10	Christopher Ryan Sullivan Chief Financial Officer	Sold10b5-1 plan	10,185	$17.62	179K	20%	Form 4
Aug 28	Mittie Doyle Chief Medical Officer	Sold10b5-1 plan	679	$20.00	14K	1.3%	Form 4
Aug 17 – 18	Christopher Ryan Sullivan Chief Financial Officer	Sold10b5-1 plan 3 parts	72,725	$19.94 average	$1.45M	65%	Form 4
Aug 17	Mittie Doyle Chief Medical Officer	Sold10b5-1 plan	1,000	$20.00	20K	1.9%	Form 4
Aug 11	Jennifer Riley Chief Strategy Officer	SoldNo plan	2,655	$19.59	52K	6.7%	Form 4
Aug 10	Mittie Doyle Chief Medical Officer	Sold10b5-1 plan	679	$20.00	14K	1.3%	Form 4
Jul 27	Mittie Doyle Chief Medical Officer	Sold10b5-1 plan	1,000	$20.00	20K	1.9%	Form 4
Jun 30	Mittie Doyle Chief Medical Officer	Sold10b5-1 plan	4,654	$20.00	93K	8.2%	Form 4
Jun 23	Mittie Doyle Chief Medical Officer	Sold10b5-1 plan	1,450	$18.00	26K	2.7%	Form 4
May 28	Mittie Doyle Chief Medical Officer	Sold10b5-1 plan	679	$16.00	11K	1.4%	Form 4
May 15	Mittie Doyle Chief Medical Officer	Sold10b5-1 plan	3,000	$18.76	56K	45%	Form 4
May 7	Christopher Ryan Sullivan Chief Financial Officer	Sold10b5-1 plan	18,606	$24.12	449K	98%	Form 4
May 5 – 6	Mittie Doyle Chief Medical Officer	Sold10b5-1 plan 6 parts	108,234	$20.61 average	$2.23M	97%	Form 4
May 6	Christopher Ryan Sullivan Chief Financial Officer	Sold10b5-1 plan 5 parts	47,000	$20.18 average	949K	99%	Form 4
May 6	Mitchell Chan Director	Sold10b5-1 plan	3,167	$22.88	72K	50%	Form 4
May 6	Paul Varki Chief Legal Officer	Sold10b5-1 plan 5 parts	75,063	$20.17 average	$1.51M	95%	Form 4
Apr 29 – 30	Christopher Ryan Sullivan Chief Financial Officer	Sold10b5-1 plan 2 parts	16,915	$13.16 average	223K	98%	Form 4
Apr 6	Mittie Doyle Chief Medical Officer	Sold10b5-1 plan	3,970	$18.01	71K	52%	Form 4
Apr 1 – 2	Christopher Ryan Sullivan Chief Financial Officer	Sold10b5-1 plan 4 parts	15,959	$16.96 average	271K	48%	Form 4
Apr 1	Mittie Doyle Chief Medical Officer	Sold10b5-1 plan	679	$16.00	11K	16%	Form 4
Mar 16	Mittie Doyle Chief Medical Officer	Sold10b5-1 plan	25,492	$16.15	412K	88%	Form 4
Nov 14, 2025	Jonathan Goldman Director	SoldNo plan 2 parts	11,367	$14.34 average	163K	100%	Form 4
Nov 12, 2024 – Nov 13, 2024	June Sherie Almenoff Director	Bought 2 parts	1,000	$12.75 average	13K	New	Form 4

Sep 1610b5-1 plan
Christopher Ryan Sullivan
Chief Financial Officer · sold 12,394 at $16.33
202K
24% of stake
Sep 1010b5-1 plan
Christopher Ryan Sullivan
Chief Financial Officer · sold 10,185 at $17.62
179K
20% of stake
Aug 2810b5-1 plan
Mittie Doyle
Chief Medical Officer · sold 679 at $20.00
14K
1.3% of stake
Aug 17 – 1810b5-1 plan
Christopher Ryan Sullivan
Chief Financial Officer · sold 72,725 at avg $19.94
$1.45M
65% of stake
Aug 1710b5-1 plan
Mittie Doyle
Chief Medical Officer · sold 1,000 at $20.00
20K
1.9% of stake
Aug 11No plan
Jennifer Riley
Chief Strategy Officer · sold 2,655 at $19.59
52K
6.7% of stake
Aug 1010b5-1 plan
Mittie Doyle
Chief Medical Officer · sold 679 at $20.00
14K
1.3% of stake
Jul 2710b5-1 plan
Mittie Doyle
Chief Medical Officer · sold 1,000 at $20.00
20K
1.9% of stake
Jun 3010b5-1 plan
Mittie Doyle
Chief Medical Officer · sold 4,654 at $20.00
93K
8.2% of stake
Jun 2310b5-1 plan
Mittie Doyle
Chief Medical Officer · sold 1,450 at $18.00
26K
2.7% of stake
May 2810b5-1 plan
Mittie Doyle
Chief Medical Officer · sold 679 at $16.00
11K
1.4% of stake
May 1510b5-1 plan
Mittie Doyle
Chief Medical Officer · sold 3,000 at $18.76
56K
45% of stake
May 710b5-1 plan
Christopher Ryan Sullivan
Chief Financial Officer · sold 18,606 at $24.12
449K
98% of stake
May 5 – 610b5-1 plan
Mittie Doyle
Chief Medical Officer · sold 108,234 at avg $20.61
$2.23M
97% of stake
May 610b5-1 plan
Christopher Ryan Sullivan
Chief Financial Officer · sold 47,000 at avg $20.18
949K
99% of stake
May 610b5-1 plan
Mitchell Chan
Director · sold 3,167 at $22.88
72K
50% of stake
May 610b5-1 plan
Paul Varki
Chief Legal Officer · sold 75,063 at avg $20.17
$1.51M
95% of stake
Apr 29 – 3010b5-1 plan
Christopher Ryan Sullivan
Chief Financial Officer · sold 16,915 at avg $13.16
223K
98% of stake
Apr 610b5-1 plan
Mittie Doyle
Chief Medical Officer · sold 3,970 at $18.01
71K
52% of stake
Apr 1 – 210b5-1 plan
Christopher Ryan Sullivan
Chief Financial Officer · sold 15,959 at avg $16.96
271K
48% of stake
Apr 110b5-1 plan
Mittie Doyle
Chief Medical Officer · sold 679 at $16.00
11K
16% of stake
Mar 1610b5-1 plan
Mittie Doyle
Chief Medical Officer · sold 25,492 at $16.15
412K
88% of stake
Nov 14, 2025No plan
Jonathan Goldman
Director · sold 11,367 at avg $14.34
163K
100% of stake
Nov 12, 2024 – Nov 13, 2024
June Sherie Almenoff
Director · bought 1,000 at avg $12.75
13K
New position

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch AVTX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with AVTX

CompareIntrinsic value

SILOSilo Pharma Inc.

$1.33+3.91%10

OWPCOne World Products Inc.

$0.00+0.00%46

BNTCBenitec Biopharma Inc.

$9.28+10.48%10

ALTAltimmune, Inc.

$2.12+3.92%10

NTHINeonC Technologies Holdings

$3.17+3.26%10

IBOImpact Biomedical Inc.

$4.10+1.99%20

IXHLIncannex Healthcare Inc.

$2.49-0.60%10

LYELLyell Immunopharma, Inc.

$15.43+43.27%10

Held by ETFs

AVTX is in 17 US ETFs. The largest of them, with AVTX's weight in each:

Spot a number that looks wrong? Check it in AVTX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing AVTX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.